Das Gesundheitswesen , Thieme Verlag Heft 12-2021, Jahrgang 83) ISSN 1439-4421 Seite(n) 965 bis 975 DOI: 10.1055/a-1630-7601 CareLit-Dokument-Nr: 318600 |
|
Zusammenfassung Ziel der Studie Die aktuelle SARS-CoV-2 Forschung fokussiert sich bisher weitgehend auf symptomatische Fälle. Die STAAB-COVID-Studie untersuchte daher die Seroprävalenz von COVID-19 in der Allgemeinbevölkerung und die psychosozialen Auswirkungen der Pandemie. Methodik Von Juni-Oktober 2020 wurden im Rahmen des STAAB-COVID-Programms, einer Unterstudie der „Häufigkeit und Einflussfaktoren auf frühe STAdien A und B der Herzinsuffizienz in der Bevölkerung (STAAB)“ Kohortenstudie, 4860 Probanden aus einer repräsentativen altersstratifizierten Stichprobe Würzburger Einwohner zur Blutabnahme und Fragebogenerhebung eingeladen. Alle Teilnehmenden erhielten zudem das Angebot, an einer Punktprävalenzerhebung (selbst-entnommener Nasenabstrich Anfang November 2020) teilzunehmen. Ergebnisse Insgesamt nahmen 3034 Probanden am STAAB-COVID-Programm teil (Antwortrate 62%). Bei 33 Teilnehmenden (1,1%; 95% Konfidenzintervall 0,7–1,5%) wurden Antikörper gegen SARS-CoV-2 nachgewiesen. Höhere Werte auf der GAD-7-Angstskala waren mit niedrigeren Raten von SARS-CoV-2-Antikörpern assoziiert (Odds Ratio=0,78 je+1 Punkt im GAD-7; 95% Konfidenzintervall 0,65–0,95). Innerhalb dieser eher ängstlichen Probandengruppe war jedoch auch die Absagerate von medizinischen Terminen erhöht (Odds Ratio=1,13 je+1 Punkt im GAD-7; 95% Konfidenzintervall 1,10–1,16). Bei sechs von insgesamt 2451 Teilnehmenden der Punktprävalenzerhebung (0,24%; 95% Konfidenzintervall 0,09–0,53%) wurde eine akute Infektion nachgewiesen. Schlussfolgerung Zwischen der ersten und zweiten COVID-19 Welle fanden wir in Würzburg eine geringe Durchseuchung mit SARS-CoV-2. Eine ängstlichere Persönlichkeit war dabei mit einer geringeren Seroprävalenz assoziiert. Die Studiendurchführung wurde durch die bereits bestehende Kohortenstudie entscheidend erleichtert. Abstract Background Research of SARS-CoV-2 has so far largely focused on symptomatic cases. The STAAB-COVID study therefore examined the seroprevalence of COVID-19 in the general population and the psychosocial effects of the pandemic. Methods From June-October 2020, a sub-study was conducted within the “Characteristics and Course of Heart Failure Stages A-B and Determinants of Progression (STAAB)” cohort study. 4,860 study participants identified from a representative age-stratified sample of Würzburg residents were asked to provide a blood sample and to fill in a questionnaire. All participants also received an offer to take part in a point prevalence assessment (nasal swab taken from the participant at the beginning of November 2020). Results A total of 3,034 subjects took part in the STAAB-COVID program (response rate 62%). Antibodies against SARS-CoV-2 were detected in 33 participants (1.1%; 95% confidence interval 0.7–1.5%). Higher values on the GAD-7 anxiety scale were associated with lower rates of SARS-CoV-2 antibodies (Odds Ratio=0.78 for each+1 point in GAD-7; 95% confidence interval 0.65–0.95). Within this rather anxious group of subjects, however, the rate of cancellation of medical appointments was also increased (Odds Ratio=1.13 for each+1 point in GAD-7; 95% confidence interval 1.10–1.16). An acute infection was detected in six of a total of 2,451 participants in the point prevalence assessment (0.24%; 95% confidence interval 0.09–0.53%). Conclusion Between the first and second COVID-19 waves in Germany, we found a low level of SARS-CoV-2 contamination in the city of Würzburg. A more anxious personality was associated with a lower seroprevalence. Conducting the study was largely facilitated by the existing cohort study. Schlüsselwörter SARS-CoV-2 - Seroprävalenz - asymptomatische Infektion - psychosoziale Belastung Key words SARS-CoV-2 - seroprevalence - asymptomatic infection - psychosocial impact Zusatzmaterial Zusatzmaterial 12 October 2021 © 2021. Thieme. All rights reserved. Georg Thieme Verlag Rüdigerstraße 14, 70469 Stuttgart, Germany Literatur 1 Rommel A, von der Lippe E, Plaß D. et al. COVID-19-Krankheitslast in Deutschland im Jahr 2020. Dtsch Arztebl International 2021; 118: 145-151 PubMedGoogle Scholar 2 Robert Koch Institut. Epidemiologischer Steckbrief zu SARS-CoV-2 und COVID-19. In: 2021 PubMedGoogle Scholar 3 Nishiura H, Kobayashi T, Miyama T. et al. Estimation of the asymptomatic ratio of novel coronavirus infections (COVID-19). International journal of infectious diseases: IJID: official publication of the International Society for Infectious Diseases 2020; 94: 154-155 DOI: 10.1016/j.ijid.2020.03.020. CrossrefPubMedGoogle Scholar 4 Byrne AW, McEvoy D, Collins AB. et al. Inferred duration of infectious period of SARS-CoV-2: rapid scoping review and analysis of available evidence for asymptomatic and symptomatic COVID-19 cases. BMJ Open 2020; 10: e039856 DOI: 10.1136/bmjopen-2020-039856. CrossrefPubMedGoogle Scholar 5 Rothe C, Schunk M, Sothmann P. et al. Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany. The New England journal of medicine 2020; 382: 970-971 DOI: 10.1056/NEJMc2001468. CrossrefPubMedGoogle Scholar 6 Lai CC, Wang JH, Hsueh PR. Population-based seroprevalence surveys of anti-SARS-CoV-2 antibody: An up-to-date review. International journal of infectious diseases: IJID: official publication of the International Society for Infectious Diseases 2020; 101: 314-322 DOI: 10.1016/j.ijid.2020.10.011. CrossrefPubMedGoogle Scholar 7 Rostami A, Sepidarkish M, Leeflang MMG. et al. SARS-CoV-2 seroprevalence worldwide: a systematic review and meta-analysis. Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases 2020; DOI: 10.1016/j.cmi.2020.10.020. CrossrefPubMedGoogle Scholar 8 Batty GD, Deary IJ, Luciano M. et al. Psychosocial factors and hospitalisations for COVID-19: Prospective cohort study based on a community sample. Brain, Behavior, and Immunity 2020; 89: 569-578 DOI: 10.1016/j.bbi.2020.06.021. CrossrefPubMedGoogle Scholar 9 Morbach C, Gelbrich G, Tiffe T. et al. Prevalence and determinants of the precursor stages of heart failure: results from the population-based STAAB cohort study. European journal of preventive cardiology 2020; 2047487320922636 DOI: 10.1177/2047487320922636. CrossrefPubMedGoogle Scholar 10 Wagner M, Tiffe T, Morbach C. et al. Characteristics and Course of Heart Failure Stages A-B and Determinants of Progression – design and rationale of the STAAB cohort study. European journal of preventive cardiology 2017; 24: 468-479 DOI: 10.1177/2047487316680693. CrossrefPubMedGoogle Scholar 11 Spitzer RL, Kroenke K, Williams JB. et al. A brief measure for assessing generalized anxiety disorder: the GAD-7. Archives of internal medicine 2006; 166: 1092-1097 DOI: 10.1001/archinte.166.10.1092. CrossrefPubMedGoogle Scholar 12 Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. Journal of general internal medicine 2001; 16: 606-613 DOI: 10.1046/j.1525-1497.2001.016009606.x. CrossrefPubMedGoogle Scholar 13 Tu Y-P, Jennings R, Hart B. et al. Swabs Collected by Patients or Health Care Workers for SARS-CoV-2 Testing. New England Journal of Medicine 2020; 383: 494-496 DOI: 10.1056/NEJMc2016321. CrossrefPubMedGoogle Scholar 14 Lindner AK, Nikolai O, Kausch F. et al. Head-to-head comparison of SARS-CoV-2 antigen-detecting rapid test with self-collected nasal swab versus professional-collected nasopharyngeal swab 2021; DOI: 10.1183/13993003.03961-2020. CrossrefPubMed 15 Rogan WJ, Gladen B. Estimating prevalence from the results of a screening test. American journal of epidemiology 1978; 107: 71-76 DOI: 10.1093/oxfordjournals.aje.a112510. CrossrefPubMedGoogle Scholar 16 Universitätsklinikum des Saarlandes. Saarländische Antikörperstudie zur Coronavirus-Infektion abgeschlossen: Institut für Virologie am Universitätsklinikum des Saarlandes legt Ergebnisse vor. In: 21.01.2021 PubMed 17 Pritsch M, Radon K, Bakuli A. et al. Prevalence and Risk Factors of Infection in the Representative COVID-19 Cohort Munich 2021; DOI: 10.2139/ssrn.3745128. CrossrefPubMed 18 Deutsches Ärzteblatt. Schlaganfall: Angst vor Ansteckung verhinderte frühzeitige Behandlung. In: 2020 PubMed 19 Peters A, Rospleszcz S, Greiser KH. et al. COVID-19-Pandemie verändert die subjektive Gesundheit. Dtsch Arztebl International 2020; 117: 861-867 CrossrefPubMedGoogle Scholar 20 Hinz A, Klein AM, Brähler E. et al. Psychometric evaluation of the Generalized Anxiety Disorder Screener GAD-7, based on a large German general population sample. Journal of affective disorders 2017; 210: 338-344 DOI: 10.1016/j.jad.2016.12.012. CrossrefPubMedGoogle Scholar 21 Spangenberg L, Brähler E, Glaesmer H. Identifying depression in the general population - a comparison of PHQ-9, PHQ-8 and PHQ-2. Zeitschrift fur Psychosomatische Medizin und Psychotherapie 2012; 58: 3-10 DOI: 10.13109/zptm.2012.58.1.3. CrossrefPubMedGoogle Scholar 22 Del Boca D, Oggero N, Profeta P. et al. Women’s and men’s work, housework and childcare, before and during COVID-19. Review of economics of the household 2020; 1-17 DOI: 10.1007/s11150-020-09502-1. CrossrefPubMedGoogle Scholar 23 Singh S, Roy D, Sinha K. et al. Impact of COVID-19 and lockdown on mental health of children and adolescents: A narrative review with recommendations. Psychiatry research 2020; 293: 113429 DOI: 10.1016/j.psychres.2020.113429. CrossrefPubMedGoogle Scholar 24 Ravens-Sieberer U, Kaman A, Erhart M. et al. Impact of the COVID-19 pandemic on quality of life and mental health in children and adolescents in Germany. European Child & Adolescent Psychiatry 2021; DOI: 10.1007/s00787-021-01726-5. CrossrefPubMedGoogle Scholar 25 Bühring P. Deutsches Ärzteblatt 2020; 117 PubMed 26 Ammar A, Brach M, Trabelsi K. et al. Effects of COVID-19 Home Confinement on Eating Behaviour and Physical Activity: Results of the ECLB-COVID19 International Online Survey. 2020; 1583 DOI: 10.3390/nu12061583. CrossrefPubMedGoogle Scholar 27 Deeks JJ, Dinnes J, Takwoingi Y. et al. Antibody tests for identification of current and past infection with SARS-CoV-2. The Cochrane database of systematic reviews 2020; 6: Cd013652 DOI: 10.1002/14651858.cd013652. CrossrefPubMedGoogle Scholar
{{detailinfo.data.api.data.document[0].apa}}
{{detailinfo.data.api.data.document[0].vancouver}}
{{detailinfo.data.api.data.document[0].harvard}}